APPENDIX 3 – SUMMARY OF MAJOR MODIFICATIONS

2013 Prohibited List

Summary of Major Modifications and Explanatory Notes

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S0: Non-Approved Substances
• It is clarified that veterinary products only refer to substances not approved for human use.

S1. Anabolic Agents

• The IUPAC names have been reviewed with the assistance of IUPAC and the appropriate changes have been introduced for the following substances :danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)
ethylestrenol (19-norpregna-4-en-17α-ol)
furazabol (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol)
methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
prostanozol(17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane)
tetrahydrogestrinone(17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one).

• Etiocholanolone has been added to the S1.b section as an example of testosterone metabolite.

The INN will be used if existing; IUPAC nomenclature will also be used when necessary for further clarity; common names will be added where considered helpful.

S2. Peptide Hormones, Growth Factors and Related Substances

• Insulins have been moved to S4.5.a (Metabolic Modulators) because it is considered a more appropriate category based on their mechanism of action. Other antidiabetic drugs, including exenatide and liraglutide are not prohibited.

Platelet-derived preparations (PRP) were previously removed from the List after consideration of the lack of any current evidence concerning the use of these methods for purposes of performance enhancement notwithstanding that these preparations contain growth factors. Despite the presence of some growth factors, current studies on PRP do not demonstrate any potential for performance enhancement beyond a potential therapeutic effect. Note that individual growth factors are still prohibited when given separately as purified substances as described in S.2.5. Intravenous use of PRP is not permitted in accordance with M2.

S3. Beta2-agonists:

• The permitted delivered (inhaled) dose of formoterol has increased to 54 micrograms over 24 hours with a corresponding increase of the urinary threshold to 40 ng/mL.

• For clarity, all optical isomers (d- and l-) where relevant, are prohibited.

It should be noted that there are differences worldwide in the labelling of the formoterol content in inhalation devices, and that the List refers to the delivered dose of formoterol and not the metered dose. The delivered dose is the dose that leaves the mouthpiece and is available for inhalation. For example, a Symbicort® Turbuhaler®/Turbohaler® labelled as containing 12 micrograms of formoterol delivers to the patient ~9 micrograms per inhalation. If two inhalations twice a day (i.e. 48 micrograms) are administered, the delivered dose is 36 micrograms, which is the maximum approved daily dose in most countries. In some countries the permitted maximum delivered dose for temporary occasional use for treatment of asthma exacerbations is 54 micrograms over 24 hours.